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Abstract 
Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to 1-
methylnicotinamide. We have previously shown that NNMT is significantly overexpressed in 
the brains of patients who have died of Parkinson’s disease, and others have shown that 
NNMT is significantly overexpressed in a variety of diseases ranging from cancer to hepatic 
cirrhosis. In vitro overexpression has revealed many cytoprotective effects of NNMT, in 
particular increased complex I activity and ATP synthesis. Although this appears to be 
mediated by an increase in 1-methylnicotinamide production, the molecular mechanisms 
involved remain unclear. In the present study, we have investigated the role that sirtuins 1, 2 
and 3, class III DNA deacetylase enzymes, known to regulate mitochondrial energy 
production and cell cycle, have in mediating the effects of NNMT upon complex I activity. 
Expression of NNMT in SH-SY5Y human neuroblastoma cells, which have no endogenous 
expression of NNMT, significantly increased the expression of all three sirtuins. siRNA-
mediated silencing of sirtuin-3 expression decreased complex I activity in NNMT-expressing 
SH-SY5Y cells to that observed in wild-type SH-SY5Y, and significantly reduced cellular 
ATP content also. These results demonstrate that sirtuin 3 is a key mediator of NNMT-
induced Complex I activity and ATP synthesis. These results further reinforce a central role 
for NNMT in the regulation of energy homeostasis and provide further mechanistic insight 
into the consequences of enhanced NNMT expression in cancer. 
 
KEYWORDS: ATP, Bioenergetics, Complex I, Nicotinamide N-methyltransferase, 
Parkinson’s disease, Cancer 
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INTRODUCTION 
Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to 1-
methylnicotinamide (MeN) using S-adenosylmethionine as cofactor [1]. In the brain, NNMT 
is expressed solely in neurons and demonstrates regional variation in expression levels [2]. 
The expression of NNMT is significantly elevated in the cerebellum and caudate nucleus of 
patients who have died of Parkinson’s disease (PD) compared to non-disease controls [2,3]. 
NNMT expression is also elevated in a number of non-neurodegenerative diseases such as 
cirrhosis, chronic obstructive pulmonary disorder and cancer [4-8].   
 
Recently, we have shown that the expression of NNMT in human neuroblastoma cells 
increased Complex I (CxI) activity, the first enzyme in the mitochondrial respiratory chain of 
which a significant (~30%) reduction is a cardinal feature of PD [9]. This increase in CxI 
activity resulted in a subsequent increase in ATP synthesis [10] and protection against a range 
of mitotoxins [10,11]. The increase in CxI activity observed was mediated via a reduction in 
the degradation of the NDUFS3 30kDa subunit of CxI [10]. As to how this occurs is unclear, 
but one such possibility is the increased production of MeN, as incubation of SH-SY5Y with 
MeN replicated the effects of NNMT upon CxI activity and NDUFS3 degradation [10]. 
Another such possibility is the induction of sirtuin (SirT) activity, class III deacetylase 
enzymes which regulate many cellular mechanisms such as energy homeostasis, cell cycle, 
and stress resistance, and whose overexpression extends lifespan in a variety of lower 
organisms and mammals [12]. NNMT, SirT1 and SirT3 are induced by calorie restriction in 
mice [13,14], and NNMT expression is required for the pro-longevity effect of the SirT1 
homologue Sir-2.1 in C. elegans, as well as having the ability, as is MeN, to increase 
longevity independent of Sir-2.1 [15]. The beneficial effects of SirTs derive in part from their 
effects upon cellular energy balance, and are thought to act as metabolic sensors via their use 
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of NAD+ as substrate [16,17]. Of particular interest is SirT3, a mitochondrial SirT which is 
involved in the regulation of ATP production via the deacetylation of proteins of CxI [18], 
and has been implicated in survivorship in elderly humans over the age of 90 [19]. Therefore 
we investigated whether NNMT expression regulates the expression of SirTs 1, 2, and 3, and 
whether SirT3 may mediate the effects of NNMT upon CxI activity.  
 
MATERIALS AND METHODS 
Unless otherwise stated, all reagents were obtained from Sigma (Poole, Dorset, UK) and were 
of the highest grade available. 
 
Cell culture 
SH-SY5Y human neuroblastoma, which do not endogenously express NNMT, and 
S.NNMT.LP human neuroblastoma, comprising SH-SY5Y stably expressing NNMT C-
terminally tagged to the V5 epitope (NNMT-V5) and produced as part of our ongoing studies 
[10,11,20], were cultured as previously described. Although SH-SY5Y do not represent a 
differentiated neurone-like model, they do exhibit pan-neuronal characteristics, express many 
neuronal markers such as synaptophysin and are readily amenable to genetic manipulation 
[10,20]. In addition, differentiation of SH-SY5Y using retinoic acid-based protocols 
significantly increases the rate of oxidative phosphorylation by increasing mitochondrial 
spare respiratory capacity [21,22]. As such, differentiation may mask many of the cellular 
effects which we wish to observe. Therefore, for the purposes of our experiments, we chose 
to use SH-SY5Y in their undifferentiated state. For all experiments, cells of passage 18 – 21 
(for SH-SY5Y) and 9 – 13 (for S.NNMT.LP) were used. The lack of endogenous NNMT 
mRNA expression in SH-SY5Y, and the confirmation of NNMT-V5 mRNA expression in 
S.NNMT.LP, was confirmed using RT-PCR as previously described [10]. The lack of 
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endogenous NNMT protein expression in SH-SY5Y, and the presence of NNMT-V5 in 
S.NNMT.LP, was confirmed using Western blotting using mouse-anti-NNMT (1:1000, 
Abcam, Cambridge, UK, ab118403) and mouse-anti-V5 (1:2000, Abcam, ab27671) as 
previously described [10]. 
 
Quantitative Western blotting analysis of protein expression 
Proteins were subjected to quantitative Western blotting as previously described [10,20] 
using either rabbit-anti-SirT1 (1:1000, Cell Signalling Technology, Danvers, Massachusetts, 
USA, #2310), rabbit-anti-SirT2 (1:1000, Cell Signalling Technology, #2313), rabbit-anti-
SirT3 (1:1000, Cell Signalling Technology, #2627), mouse-anti-NDUFA6 (0.1 µg/mL, Life 
Technologies, Paisley, UK, A31856) or anti-acetylated lysine monoclonal antibody (1:1000, 
Cell Signalling Technology, #9861), combined with horseradish peroxidase-conjugated anti-
rabbit or anti-mouse IgG as appropriate (1:2000, Sigma). To normalise for protein 
concentration, membranes were stripped using Restore™ Western Stripping Reagent (Fisher 
Scientific, Loughborough, UK) and re-probed using a combination of mouse-anti-β-tubulin 
(1:2000, Abcam, ab7792) and rabbit-anti-mouse IgG, horseradish peroxidase conjugate 
(1:5000, Sigma). Images were digitally captured, band intensities quantified via densitometric 
analysis (with the exception of anti-acetylated lysine) using ImageLab software (BioRad, 
Hemel Hempstead, UK) and normalised for β-tubulin expression. Results were expressed as 
percentage expression compared to that observed in SH-SY5Y cells ± S.D (n = 4 for SirTs, n 
= 3 for NDUFA6). 
 
siRNA-mediated silencing of SIRT3 expression 
SIRT3 expression was silenced in S.NNMT.LP cells as previously described [20] using three 
pooled SirT3 siRNA sequences (sc-61555, Santa Cruz Biotechnology, Heidelberg, Germany) 
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(S.NNMT.LPKD), with a scrambled sequence siRNA (sc-37007, Santa Cruz Biotechnology) 
serving as a control (S.NNMT.LPScr). SIRT3 silencing was confirmed using RT-PCR [20] 
using the following primer pair: forward primer, 5’-CTGTACAGCAACCTCCAGCA-3’, 
reverse primer, 5’-GCTCCCCAAAGAACACAATG-3’. GAPDH loading control was 
detected using the following primer pair: forward primer, 5’-
AGCCACATCGCTCAGACAC-3’, reverse primer, 5’-GCCCAATACGACCAAATCC-3’. 
Reduction in SirT3 protein expression was confirmed using Western blotting as described 
above. As a control to ensure that the transfection procedure had no effect upon SirT3 
expression and analysis endpoints, S.NNMT.LP cells were also incubated with transfection 
reagent alone for 72 hours (S.NNMT.LPCtrl). 
 
Complex I activity analysis 
CxI activity in SH-SY5Y, S.NNMT.LP, S.NNMT.LPCtrl, and S.NNMT.LPKD was assessed as 
previously described [10,23]. Experiments were performed in triplicate using 6 samples per 
experiment, and were expressed as percentage of CxI activity observed in the appropriate 
experimental control ± S.D.  
 
ATP analysis 
Cellular ATP content was assessed in S.NNMT.LPCtrl and S.NNMT.LPKD using the ATP-
Glo™ Bioluminetric Cell Viability Assay Kit (Cambridge Bioscience, Cambridge, UK) as 
previously described [20,23]. Experiments were performed seven times using 11 samples per 
experiment. Results were calculated and expressed as percentage observed in the appropriate 
experimental control ± S.D. 
 
Statistical analysis 
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All statistical analyses were performed using the Prism statistical package (GraphPad, La 
Jolla, USA). Statistical comparisons were performed using student’s t-test with Welch 
correction, with the exception of the effect of siRNA silencing of SIRT3 upon cellular ATP 
content, which was performed using 1-way ANOVA with Tukey’s post hoc multiple 
comparisons test. P values of less than 0.05 were taken as significant. 
 
RESULTS 
FIG.1 
S.NNMT.LP cells expressed recombinant NNMT-V5 and demonstrated increased Complex I 
activity 
The endogenous and recombinant expression of NNMT was assessed in SH-SY5Y and 
S.NNMT.LP using a combination of RT-PCR and Western blotting (Fig. 1A & 1B). Neither 
endogenous NNMT mRNA nor protein was detected in SH-SY5Y, whereas recombinant 
NNMT-V5 was expressed in S.NNMT.LP. In accord with our previous studies [10], CxI 
activity was significantly increased in S.NNMT.LP cells compared to SH-SY5Y (100 ± 
25.9% vs. 209.3 ± 44.4%, n = 3, p = 0.035) (Fig. 1C). 
 
The stable expression of NNMT-V5 increased SirT protein expression and activity 
FIG.2 
In order to identify a potential molecular target which mediated the effect of NNMT-V5 upon 
CxI activity, we focussed upon SirTs 1, 2 and 3 which we compared in SH-SY5Y and 
S.NNMT.LP cells using quantitative Western blotting (Fig. 2A & 2B). SirT1 expression, 
detected as a protein of approximately 95 kDa [24], was almost undetectable in SH-SY5Y 
cells yet was significantly increased in S.NNMT.LP cells (100 ±  11.5 % vs. 1760 ± 138.4 %, 
n = 4, p < 0.001). SirT2, detected as a protein of approximately 39 kDa (corresponding to the 
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molecular weight of isoform 2) [25], was expressed in both cell-lines, which was 
significantly increased in S.NNMT.LP cells (100 ± 8.9 vs. 246.1 ± 71.7 %, n = 4, p = 0.027). 
SirT3, detected as a protein of approximately 31 kDa (corresponding to the molecular weight 
of post-translationally-processed SirT3) [26], was almost undetectable in SH-SY5Y, yet was 
significantly expressed in S.NNMT.LP cells (100 ± 9.6% vs. 1835.5 ± 129.8%, n = 4, p < 
0.001).  
 
Protein acetylation was widespread in the SH-SY5Y proteome (Fig. 2C), with the majority of 
acetylated proteins having a MWt below 200 kDa. Protein acetylation was significantly 
reduced in the S.NNMT.LP proteome, with proteins greater than 100 kDa exhibiting little or 
no acetylation, demonstrating an increase in SirT activity in S.NNMT.LP cells. 
 
Silencing SIRT3 expression decreased Complex I activity and cellular ATP content 
FIG. 3 
Having demonstrated that NNMT-V5 expression increased the expression of SirTs 1, 2 and 3, 
we focussed upon SirT3, as this SirT is known to regulate oxidative phosphorylation by the 
direct deacetylation of subunits of the mitochondrial respiratory chain [27], in particular 
NDUFA9 of CxI [18]. Silencing SIRT3 expression reduced SIRT3 mRNA expression in 
S.NNMT.LPKD (Fig. 3A), with a concomitant reduction in protein expression (100 ± 29% vs. 
8.4 ± 1.2%, n = 3, p = 0.032) (Fig. 3B).  Scrambled siRNA had no effect upon SIRT3 mRNA 
expression (Fig. 3A). 
 
CxI activity was not significantly altered in S.NNMT.LPCtrl cells compared to S.NNMT.LP, 
demonstrating that the siRNA procedure had no effect upon CxI activity (data not shown). In 
contrast, CxI activity was significantly reduced in S.NNMT.LPKD compared to 
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S.NNMT.LPCtrl (100 ± 21.2% vs. 62.8 ± 2.7%, n = 3, p = 0.048) (Fig. 3C), which was not 
significantly different to that observed in SH-SY5Y cells (131.5 ± 5.6%, n = 3, p = 0.18). 
Likewise, cellular ATP content was not significantly different in S.NNMT.LPCtrl compared to 
S.NNMT.LP (88.7% ± 8.1% of that observed in S.NNMT.LP, n = 7, p > 0.05), whereas 
cellular ATP content was significantly reduced in S.NNMT.LPKD compared to 
S.NNMT.LPCtrl (100 ± 9.8% vs. 66.3 ± 11.6%, n = 7, p < 0.001) (Fig. 3D). ATP content in 
S.NNMT.LPKD was significantly higher than that observed in SH-SY5Y cells (100 ± 4.6% 
vs. 275.1 ± 15.8%, n = 7, p < 0.001).    
 
Increased Complex I activity and ATP synthesis did not arise from an increase in 
mitochondrial number 
FIG. 4 
It is possible that the NNMT-V5-mediated increase in CxI activity, and subsequent ATP 
synthesis, was due to an increase in mitochondrial number. Although the calculation of CxI 
activity takes into account mitochondrial number and as such demonstrated an increase in 
enzyme activity, it does not rule out an increase in mitochondrial number being in some part 
responsible for the increase in cellular ATP synthesis observed in S.NNMT.LP cells [10]. 
Therefore, the expression of the CxI subunit NDUFA6 with respect to the cytosolic 
housekeeping protein β-tubulin was used as a surrogate measure of mitochondrial number 
(Fig. 4). NDUFA6 was detected as a 15 kDa protein in both cells lines at similar levels in 
each (100 ± 9.7% vs. 114 ± 10.2%, n = 4, p = 0.207) (Fig. 4A). 
 
DISCUSSION 
NNMT is central to the regulation of energy balance within the cell 
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Recent studies which provide compelling evidence of a role for NNMT in the regulation of 
energy metabolism and cell survival in vitro [10,11,14], in particular NNMT’s ability to 
induce CxI activity, ATP synthesis and synapse formation [10,20], have transformed NNMT 
from merely a Phase II enzyme into a key mediator of many fundamental processes essential 
for the maintenance of cellular health and function. This effect upon CxI is of particular 
interest, as reduced CxI activity is a cardinal feature of PD [9]. In order to understand more 
fully how NNMT is able to regulate CxI activity and ATP synthesis, we have investigated 
whether NNMT-V5 influences the expression of SirTs.  
 
We investigated SirTs for a number of reasons: (1) SirTs 1 & 3 have been shown to regulate 
mitochondrial functions such as biogenesis, oxidative phosphorylation and ATP synthesis 
[18,19,28,29], (2) SirT3 has been shown to regulate the activity of CxI via the deacetylation 
of the lysine residues of NDUFA9 [18], and (3) NNMT is induced along with SirT1 and 
SirT3 during calorie restriction [13,14]. We did not investigate the effects of NNMT-V5 
expression upon the remaining SirTs, in particular SirTs 4 & 5, because although these two 
SirTs are expressed in the mitochondria alongside SirT3, they are involved in the regulation 
of amino acid metabolism and the urea cycle respectively, with no research to date reporting 
either a direct or indirect effect upon oxidative phosphorylation [27,30,31].  
 
The demonstration that NNMT-V5 expression induced SirT expression and activity 
reinforces its pivotal role in regulating energy metabolism and mitochondrial function in the 
cell. SirT activation most likely arises from the increased metabolism of nicotinamide, the 
physiological inhibitor of SirTs [32]. This is supported by Schmeisser and colleagues in C. 
elegans [15] who demonstrated that knock-out of the NNMT homologue anmt-1 inhibited the 
pro-longevity effects of the SirT1 homologue Sir-2.1, with the overexpression of anmt-1 
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having the opposite effect. As to how NNMT-V5 induced SirT expression is unclear. It is 
possible that MeN, the metabolic product of NNMT N-methylation of nicotinamide, may be 
responsible, which is supported by our previous studies that demonstrated that MeN 
increased CxI activity and cellular ATP content in SH-SY5Y cells [10,11]. In accord with 
this, Xie et al. [33] reported that increased MeN production was responsible for the NNMT-
mediated increase in cellular ATP content in human colorectal cancer cells. SirTs are also 
thought to act as metabolic sensors via their use of NAD+ as substrate [16,17], whose 
availability is regulated by NNMT via NAD+ synthesis [3,34]. Both NAD+ and NADH 
levels are decreased in S.NNMT.LP compared to SH-SY5Y cells [10], demonstrating that 
pyridine nucleotide synthesis is decreased due to reduced nicotinamide availability, however 
the NAD+:NADH ratio was also significantly reduced in S.NNMT.LP compared to SH-
SY5Y, indicating increased use of NAD+ presumably via increased SirT activity. Hence, the 
ability of NNMT to induce and activate SirT activity places it firmly within the regulation of 
mitochondrial function and energy regulation. 
 
SirT3 is a key mediator of NNMT’s effect upon Complex I activity 
The decrease in CxI activity in S.NNMT.LPKD, which was comparable to that observed in 
SH-SY5Y cells, arising from the silencing of SirT3 expression demonstrates that SirT3 
mediates the effects of NNMT-V5 upon CxI activity. This is in accord with SirT3’s ability to 
activate CxI activity via the deacetylation of NDUFA9 [18]. What was interesting was that 
cellular ATP content was not reduced to levels observed in SH-SY5Y cells, indicating that 
mechanisms other than SirT3 are also involved. One such possibility is an increase in 
mitochondrial number, however the relative expression of NDUFA6, whose expression 
relative to the cytosolic housekeeping gene β-tubulin would be expected to increase if 
mitochondrial number were increased also, did not change, which is in accord with the lack 
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of change in NDUFS9 expression that we have previously reported [10]. The induction of 
SirT1 expression, which increases mitochondrial ATP synthesis via the induction of other 
targets not part of oxidative phosphorylation such as PPAR-γ and PGC1α [28], that we 
observed may contribute to the increase in cellular ATP content in S.NNMT.LP. What is 
clear, however, is that SirT3 mediates the induction of CxI activity by NNMT-V5, most 
likely due to increased deacetylation. 
 
Induction of NNMT expression in the Parkinsonian brain may be a stress response of 
the cell to the underlying disease pathogenesis 
The S.NNMT.LP cell-line does not closely mimic the dopaminergic neuronal phenotype of 
the neurons which degenerate in PD, indeed it was our sole original intention to model 
NNMT expression using a cell-line which has no endogenous expression of NNMT, to 
provide the ability to investigate the biochemical effects of NNMT upon the cell in isolation 
[10,11,20]. However, this originated from our research into the expression of NNMT in 
human PD brain tissue [2,3], thus our studies provide evidence for what may be occurring 
biochemically within the dopaminergic neuron in the PD brain. Accumulating evidence from 
these studies suggest that the increased expression of NNMT that we have observed in vivo 
induces SirT expression and hence increases CxI activity and ATP synthesis, alongside 
increased synapse formation and protection from PD-relevant mitotoxins, as part of a 
cytoprotective response of the neuron to the PD pathogenic process. NNMT is also induced 
in a number of cancers, such as breast and neuroblastoma (from which SH-SY5Y cells are 
derived). Such induction has several beneficial consequences for the tumour cell, namely 
reduced radiation sensitivity via the metabolism of the radiosensitizer nicotinamide [35], 
promotion of metastasis via the induction of the Akt signalling pathway [36] and protection 
against a range of cytotoxins [10,11]. It is likely that such induction provides the high energy 
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demand, namely increased cellular ATP content, required by the tumour cell. In support of 
this, SirT3 protein levels are elevated in breast cancers [37]. 
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Figure legends 
Fig. 1. S.NNMT.LP express NNMT-V5 and demonstrate increased Complex I activity. 
(A) mRNA expression. NNMT and NNMT-V5 mRNA expression was detected using RT-
PCR, with equal loading confirmed using GAPDH. (B) Protein expression. NNMT and 
NNMT-V5 protein expression was detected using Western blotting, with equal protein 
loading confirmed using β-tubulin. (C) Complex I activity. Complex I activity was assessed 
using a colourimetric-based assay. Statistical analysis was performed using t-test with Welch 
correction (n = 3). 
 
Fig. 2. Expression of NNMT-V5 in S.NNMT.LP increased the expression of SirTs 1, 2 
and 3 and decreased protein acetylation. (A) Sirtuin protein expression. SirTs 1, 2 and 3 
protein expression was detected using Western blotting. (B) Quantitative analysis. Band 
intensities were quantified using densitometry using ImageLab, normalised for β-tubulin and 
expressed as percentage expression compared to SH-SY5Y. Statistical analysis comprised t-
test with Welch correction (n = 4). (C) Proteome acetylation. SH-SY5Y and S.NNMT.LP 
proteome acetylation was assessed using Western blotting. For all panels: SirT1: sirtuin-1; 
SirT2: sirtuin-2; SirT3: sirtuin-3. 
 
Fig. 3. siRNA silencing of SIRT3 expression in S.NNMT.LP reversed the effect of 
NNMT-V5 expression upon Complex I activity, and reduced cellular ATP content. 
SIRT3 expression was silenced using transient transfection of S.NNMT.LP with 3 pooled 
siRNA (S.NNMT.LPKD). As controls, S.NNMT.LP incubated with transfection medium 
alone (S.NNMT.LPCtrl) and S.NNMT.LP transfected with scrambled sequence siRNA 
(S.NNMT.LPScr) were used. (A) SIRT3 mRNA expression. SIRT3 expression was assessed 
using RT-PCR. (B) SirT3 protein expression. Sirtuin-3 expression was assessed using 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 20 of 20 
 
Western blotting. (C) Complex I activity. Complex I activity was analysed using a 
colourimetric assay. Statistical analysis comprised t-test with Welch correction (n = 3). (D) 
Cellular ATP content. Cellular ATP content was assessed using the ATP-Glo 
bioluminescence assay. Statistical analysis comprised one-way ANOVA with Tukey’s post 
hoc comparisons test (n = 7). For all panels: S.NNMT.LPCtrl = S.NNMT.LP cells incubated 
with siRNA transfection reagent only; S.NNMT.LPScr = S.NNMT.LP cells incubated with 
scrambled siRNA; S.NNMT.LPKD = S.NNMT.LP cells incubated with 3 pooled siRNA 
sequences targeting SIRT3. 
 
Fig. 4. Expression of NNMT-V5 in S.NNMT.LP did not alter mitochondrial number. As 
a measure of mitochondrial number, the expression of the Complex I subunit NDUFA6 was 
measured and compared to the expression of the cytosolic protein β-tubulin. (A) Western 
blotting. NDUFA6 was detected using Western blotting. (B) Quantitative analysis. Bands 
were quantified and analysed using densitometry, normalised for β-tubulin expression and 
expressed as percentage expression compared to SH-SY5Y cells. Statistical analysis 
comprised t-test with Welch correction (n = 3). 
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• Nicotinamide N-methyltransferase induced Complex I activity 
• Nicotinamide N-methyltransferase induced expression and activity of sirtuins 1 – 3 
• Sirtuin-3 mediated effects of nicotinamide N-methyltransferase upon complex 1 
• Nicotinamide N-methyltransferase has a central role in mitochondrial bioenergetics 
